Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
100 hedge funds and large institutions have $276M invested in Syros Pharmaceuticals, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 48 increasing their positions, 20 reducing their positions, and 25 closing their positions.
140% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 20
6% less funds holding
Funds holding: 106 → 100 (-6)
24% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 25
42% less capital invested
Capital invested by funds: $475M → $276M (-$200M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
66% less call options, than puts
Call options by funds: $893K | Put options by funds: $2.66M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
+$5.62M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.04M |
| 3 |
SCM
Sio Capital Management
New York
|
+$4.74M |
| 4 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$4.22M |
| 5 |
AG
Artal Group
Luxembourg
|
+$4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$57.7M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$38.6M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
-$37.7M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$3.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$3.65M |
SYRS Hedge Fund Activity: Q2 2021 in Review
100 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q2 2021, worth a combined $276M — down 42% from $475M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of SYRS and 19 opened new positions — a net loss of 6 holders — while 20 trimmed existing stakes and 48 added.
The largest buyer was Altium Capital Management, adding an estimated $5.62M. The largest seller was ARK Investment Management, exiting entirely with an estimated $57.7M sold.
- 100 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q2 2021, down from 106 in Q1 2021.
- Funds reported $276M of Syros Pharmaceuticals, Inc. Common Stock stock for Q2 2021, down 42% quarter-over-quarter.
- 19 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q2 2021 and 25 closed out, a net change of -6 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q2 2021 was Altium Capital Management, an estimated $5.62M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q2 2021 was ARK Investment Management, an estimated $57.7M sold.
Based on aggregated 13F filings for Q2 2021.